Research programme: therapeutic agents - Celltech Group/Medarex/Genmab
Alternative Names: Breast cancer research programme - Celltech Group/Medarex; HuMax-Cancer; MDX 067; MDX-OGS 001; OGS-MDX 067; Research programme: breast cancer - Celltech Group/MedarexLatest Information Update: 03 May 2007
At a glance
- Originator Genmab; Medarex; UCB
- Developer UCB
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Heparanase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 03 May 2007 Discontinued - Preclinical for Breast cancer in England (unspecified route)
- 08 Dec 2003 The integration of Oxford GlycoSciences into Celltech Group has been completed
- 12 Aug 2003 Oxford GlycoSciences has been acquired by Celltech Group